About: Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses
Creator	Kanekiyo, Masaru Tsybovsky, Yaroslav Andrews, Sarah Mascola, John Corbett, Kizzmekia Crank, Michelle Graham, Barney Mcdermott, Adrian Moin, Syed Yassine, Hadi Boyington, Jeffrey Fisher, Brian Boyoglu-Barnum, Seyhan Gillespie, Rebecca Hutchinson, Geoffrey Lederhofer, Julia Stephens, Tyler Vaile, John
source	PMC
abstract	The conserved hemagglutinin (HA) stem has been a focus of universal influenza vaccine efforts. Influenza A group 1 HA stem-nanoparticles have been demonstrated to confer heterosubtypic protection in animals; however, the protection does not extend to group 2 viruses, due in part to differences in glycosylation between group 1 and 2 stems. Here, we show that introducing the group 2 glycan at Asn38(HA1) to a group 1 stem-nanoparticle (gN38 variant) based on A/New Caledonia/20/99 (H1N1) broadens antibody responses to cross-react with group 2 HAs. Immunoglobulins elicited by the gN38 variant provide complete protection against group 2 H7N9 virus infection, while the variant loses protection against a group 1 H5N1 virus. The N38(HA1) glycan thus is pivotal in directing antibody responses by controlling access to group-determining stem epitopes. Precise targeting of stem-directed antibody responses to the site of vulnerability by glycan repositioning may be a step towards achieving cross-group influenza protection.
has issue date	2020-02-07(xsd:dateTime)
bibo:doi	10.1038/s41467-020-14579-4
bibo:pmid	32034141
has license	cc-by
sha1sum (hex)	69069a32e0361f1ade789e992a780e490854775f
schema:url	https://doi.org/10.1038/s41467-020-14579-4
resource representing a document's title	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses
has PubMed Central identifier	PMC7005838
has PubMed identifier	32034141
schema:publication	Nat Commun
resource representing a document's body	covid:69069a32e0361f1ade789e992a780e490854775f#body_text
is schema:about of	named entity 'antibody' named entity 'antibody' named entity 'NHS' named entity 'NaCl' named entity 'gene' named entity 'Passive transfer' named entity 'antibodies' named entity 'CR6261' named entity 'neutralizing antibody' named entity 'ion exchange chromatography' named entity 'nanoparticle' named entity 'pseudoviruses' named entity 'polyclonal' named entity 'antibody' named entity 'CR6261' named entity 'glycosylation pattern' named entity 'pandemic strains' named entity 'immunogenetic' named entity 'lysis buffer' named entity 'hydrophobic' named entity 'mAbs' named entity 'mAbs' named entity 'human influenza' named entity 'virus' named entity 'antibodies' named entity 'antigen' named entity 'ThermoFisher Scientific' named entity 'VDJ' named entity 'Arg' named entity 'CCD camera' named entity 'NIH' named entity 'glycan' named entity 'wild-type' named entity 'statistical significance' named entity 'glycans' named entity 'immune sera' named entity 'Luciferase' named entity 'New Caledonia' named entity 'immune sera' named entity 'Bonferroni correction' named entity 'viruses' named entity 'PDB' named entity 'animal models' named entity 'U.S.' named entity 'cross-reactive' named entity 'cryo-EM' named entity 'cross-reactive' named entity 'H7N9' named entity 'virus' named entity 'antibody-mediated' named entity 'pH 8' named entity 'protomer' named entity 'lentiviruses' named entity 'IgG' named entity 'Immune sera' named entity 'approximate location' named entity 'streptomycin' named entity 'Immunization' named entity 'animal species' named entity 'antibody' named entity 'serum' named entity 'weight loss' named entity 'antibody' named entity 'nanoparticle'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software